The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.
about
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-AnalysisVasomotor reactivity comparison in multiple sclerosis patients with white matter lesions and nonmultiple sclerosis subjects with white matter lesions in brain magnetic resonance imaging.Emerging immunopharmacological targets in multiple sclerosis.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Daclizumab.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Regulatory T Cells As Potential Targets for HIV Cure Research.
P2860
Q26776234-F26B32D8-1CC1-47C3-A32E-52A1765585E6Q30699740-4B1A9C84-11F4-49E9-8440-EE32B0AD8370Q33755345-C4B0C5B4-0EBF-4314-AE75-A4E7A853A770Q35959784-DA127788-2A72-4E8B-B10A-6551499F68CCQ36629063-51890DCF-7FAA-4A0F-B957-DD409F803401Q37559970-7F5A200F-E0A9-4447-AAB0-3688330BB5CDQ38397484-F554DE4D-8421-43C9-9736-466B408E0562Q42700892-733CDF3A-B539-493A-B8A9-3BB06F0F83AAQ43073589-AA8CE9A8-00FB-44F0-80F6-A3FEFEC1AB75Q45066717-F82560E1-F3BA-407D-B7DF-2BD6477C55F3Q46487963-19975BB0-F33B-4D14-9BBB-F32A0C0F10FFQ47868767-CF1D7858-4172-4704-9956-44EA2999DED4Q52715799-207D0E59-3236-42A2-89CA-CF1CF2EFFBA6
P2860
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@ast
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@en
type
label
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@ast
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@en
prefLabel
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@ast
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@en
P2860
P356
P1476
The efficacy and safety of dac ...... eatment of multiple sclerosis.
@en
P2093
P2860
P356
10.1177/1756285613504021
P50
P577
2014-01-01T00:00:00Z